New study published in Genetics in Medicine reveals transformative impact of Ambry's Patient for Life reanalysis program.

Valued at a market cap of $9.2 billion, Tempus AI (TEM) stock went public in June 2024. Since its initial public offering, ...

Tempus AI delivered strong Q1 results, driven by the Ambry Genetics acquisition and a major AstraZeneca contract, boosting ...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics defeated an appeal by Myriad Genetics to block competing DNA-based tests to determine hereditary risk for breast and ovarian cancer after a ...

Konica Minolta has agreed to acquire Ambry Genetics for up to $1 billion, the companies said on July 5, 2017, in a deal the buyer envisions as the first step in its strategy of developing a ...

Shares of Tempus AI TEM gained 18.4% after it announced an agreement, on Nov. 4, 2024, to acquire Ambry Genetics for $600 million. This acquisition will likely help Tempus revolutionize healthcare ...

Aliso Viejo-based Ambry Genetics Corp. on Nov. 4 announced an agreement to be acquired for $600 million by Tempus AI Inc. “They’ve achieved one of the rare things in our space where you actually have ...

Financing was provided by Ares Management Credit funds. Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. Tempus is a technology ...

Peer-reviewed publication examines the benefits of proactive exome reanalysis on diagnostic outcomes Ambry Genetics’ Patient for Life program is supported by a dedicated team of scientists who ...